[2-hydroxy-5-(3,5,7-trihydroxy-3,4-dihydro-2H-chromen-2-yl)phenyl] 3,4,5-trihydroxybenzoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: [2-hydroxy-5-(3,5,7-trihydroxy-3,4-dihydro-2H-chromen-2-yl)phenyl] 3,4,5-trihydroxybenzoate
• 化学式: C₂₂H₁₈O₁₀
• 分子量: 442.4
• InChiKey: GNXIIYFUGQWDJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  177
• 氢给体数：
  7
• 氢受体数：
  10

文献信息

• PERITONEAL THERAPEUTIC FLUID
  申请人：Opterion Health AG

  公开号：EP3120842A1

  公开（公告）日：2017-01-25

  Peritoneal therapeutic fluid comprising one or more of a biocompatibility enhancing agent (BCA) that is selected from the group consisting of a polyphenolic compound, a metabolite of a polyphenolic compound which is obtained by metabolization in the human or animal body, a salt or a glycoside of a polyphenolic compound.

  含有一种或多种生物相容性增强剂（BCA）的腹膜治疗液，这种生物相容性增强剂选自多酚类化合物、多酚类化合物在人或动物体内代谢产生的代谢产物、多酚类化合物的盐或糖苷组成的组。
• AQUEOUS SOLUTION COMPRISING A POLYPHENOL
  申请人：Opterion Health AG

  公开号：EP3120838A1

  公开（公告）日：2017-01-25

  Aqueous solution, comprising, in dissolved state, - at least one polyphenolic compound (e. g. resveratrol or piceid) - at least one saccharide (e. g. glucose or icodextrin), and method for increasing the solubility of a polyphenolic compound in water

  水溶液，以溶解状态包含 - 至少一种多酚类化合物（如白藜芦醇或 piceid） - 至少一种糖类（如葡萄糖或冰糖糊精）、 以及提高多酚类化合物在水中溶解度的方法
• Peritoneal therapeutic fluid
  申请人：OPTERION Health AG

  公开号：US11160766B2

  公开（公告）日：2021-11-02

  Peritoneal therapeutic fluid comprising one or more of a biocompatibility enhancing agent (BCA) that is selected from the group consisting of a polyphenolic compound, a metabolite of a polyphenolic compound which is obtained by metabolization in the human or animal body, a salt or a glycoside of a polyphenolic compound.

  含有一种或多种生物相容性增强剂（BCA）的腹膜治疗液，这种生物相容性增强剂选自多酚类化合物、多酚类化合物在人或动物体内代谢产生的代谢产物、多酚类化合物的盐或糖苷组成的组。
• [EN] PERITONEAL THERAPEUTIC FLUID<br/>[FR] FLUIDE THÉRAPEUTIQUE PÉRITONÉAL
  申请人：OPTERION HEALTH AG

  公开号：WO2017013120A1

  公开（公告）日：2017-01-26

  Peritoneal therapeutic fluid comprising one or more of a biocompatibility enhancing agent (BCA) that is selected from the group consisting of a polyphenolic compound, a metabolite of a polyphenolic compound which is obtained by metabolization in the human or animal body, a salt or a glycoside of a polyphenolic compound.